Drug trials for treatment of human angiostrongyliasis
Rev. Inst. Med. Trop. Säo Paulo
; Rev. Inst. Med. Trop. Säo Paulo;45(4): 179-184, July-Aug. 2003.
Article
in En
| LILACS
| ID: lil-345379
Responsible library:
BR1.1
ABSTRACT
Abdominal and cerebral angiostrongyliasis are two important infections produced by metastrongylid worms, the former occurring in Central and South America and the later in Asia and Pacific Islands. Drug treatment is a challenge since the worms and its evolving larvae live or migrate inside vessels and efficient killing of the parasites may produce more severe lesions. Larvicidal effect of certain drugs appears to be more easily accomplished but this outcome is not useful in abdominal angiostrongyliasis since clinical manifestations appear to result from sexual maturation of the worms. We review the drug trials in murine experimental models and conclude that most of them could not be considered good candidates for treatment of human infection, except for PF1022A, pyrantel and flubendazole
Full text:
1
Collection:
01-internacional
Database:
LILACS
Main subject:
Strongylida Infections
/
Angiostrongylus
/
Anthelmintics
Limits:
Animals
Language:
En
Journal:
Rev. Inst. Med. Trop. Säo Paulo
Journal subject:
MEDICINA TROPICAL
Year:
2003
Document type:
Article
Affiliation country:
Brazil
Country of publication:
Brazil